Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
$2.52
-3.6%
$2.34
$0.82
$4.98
$621.93M2.543.05 million shs3.61 million shs
DocGo Inc. stock logo
DCGO
DocGo
$1.53
$1.89
$1.23
$5.68
$156.03M0.94787,559 shs691,583 shs
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
$20.01
$20.00
$4.95
$20.68
$957.54M-0.94847,595 shs1 shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$9.78
-3.5%
$8.50
$6.44
$17.00
$753.91M0.63909,889 shs1.20 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
-3.82%+5.67%+7.25%-1.57%+169.59%
DocGo Inc. stock logo
DCGO
DocGo
0.00%+6.25%+5.88%-46.69%-52.63%
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
0.00%0.00%0.00%0.00%0.00%
Replimune Group, Inc. stock logo
REPL
Replimune Group
-3.46%+0.93%+24.43%-17.54%+8.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
2.1014 of 5 stars
3.51.00.00.01.82.50.6
DocGo Inc. stock logo
DCGO
DocGo
3.473 of 5 stars
3.33.00.00.03.02.51.9
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
4.1442 of 5 stars
3.61.00.04.52.82.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
3.00
Buy$4.0059.05% Upside
DocGo Inc. stock logo
DCGO
DocGo
2.50
Moderate Buy$3.56132.68% Upside
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
0.00
N/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
3.14
Buy$20.83113.02% Upside

Current Analyst Ratings Breakdown

Latest BFLY, FMTX, DCGO, and REPL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$14.00 ➝ $22.00
5/12/2025
DocGo Inc. stock logo
DCGO
DocGo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$5.00 ➝ $1.45
5/9/2025
DocGo Inc. stock logo
DCGO
DocGo
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$4.00 ➝ $3.00
5/9/2025
DocGo Inc. stock logo
DCGO
DocGo
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/5/2025
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $4.00
4/8/2025
DocGo Inc. stock logo
DCGO
DocGo
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
3/17/2025
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
$85.63M7.26N/AN/A$1.06 per share2.37
DocGo Inc. stock logo
DCGO
DocGo
$520.50M0.30$0.06 per share23.62$2.93 per share0.52
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
$100.56M9.52N/AN/A$10.51 per share1.90
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/A$6.26 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
-$133.70M-$0.29N/AN/AN/A-129.25%-42.68%-30.31%8/7/2025 (Estimated)
DocGo Inc. stock logo
DCGO
DocGo
$6.86M-$0.025.4619.1314.164.35%8.90%5.72%8/6/2025 (Estimated)
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
-$172.96M-$4.00N/AN/AN/AN/A-39.68%-35.33%N/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$215.79M-$3.07N/AN/AN/AN/A-54.84%-42.97%8/6/2025 (Estimated)

Latest BFLY, FMTX, DCGO, and REPL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/22/2025Q4 2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$0.75-$0.82-$0.07-$0.82N/AN/A
5/8/2025Q1 2025
DocGo Inc. stock logo
DCGO
DocGo
-$0.01-$0.09-$0.08-$0.09$104.25 million$96.03 million
5/2/2025Q1 2025
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
-$0.09-$0.06+$0.03-$0.06$21.16 million$21.23 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
N/AN/AN/AN/AN/A
DocGo Inc. stock logo
DCGO
DocGo
N/AN/AN/AN/AN/A
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
N/AN/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
N/A
4.66
2.95
DocGo Inc. stock logo
DCGO
DocGo
N/A
2.19
2.19
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
N/A
12.74
12.74
Replimune Group, Inc. stock logo
REPL
Replimune Group
0.14
11.43
11.43

Institutional Ownership

CompanyInstitutional Ownership
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
37.85%
DocGo Inc. stock logo
DCGO
DocGo
56.44%
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
87.39%
Replimune Group, Inc. stock logo
REPL
Replimune Group
92.53%

Insider Ownership

CompanyInsider Ownership
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
25.18%
DocGo Inc. stock logo
DCGO
DocGo
2.70%
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
5.79%
Replimune Group, Inc. stock logo
REPL
Replimune Group
8.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
460247.29 million154.94 millionOptionable
DocGo Inc. stock logo
DCGO
DocGo
2,920101.98 million99.30 millionOptionable
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
16647.85 million45.08 millionNot Optionable
Replimune Group, Inc. stock logo
REPL
Replimune Group
21077.09 million70.24 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Butterfly Network stock logo

Butterfly Network NYSE:BFLY

$2.52 -0.10 (-3.64%)
Closing price 06/11/2025 03:59 PM Eastern
Extended Trading
$2.53 +0.01 (+0.44%)
As of 06/11/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

DocGo stock logo

DocGo NASDAQ:DCGO

$1.53 0.00 (0.00%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$1.58 +0.05 (+3.27%)
As of 06/11/2025 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.

Forma Therapeutics stock logo

Forma Therapeutics NASDAQ:FMTX

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.

Replimune Group stock logo

Replimune Group NASDAQ:REPL

$9.78 -0.35 (-3.46%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$9.96 +0.18 (+1.84%)
As of 06/11/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.